Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.

McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, Li M, Sitbon O, Tapson V, Frost A.

Chest. 2019 Nov 16. pii: S0012-3692(19)34214-X. doi: 10.1016/j.chest.2019.10.043. [Epub ahead of print]

2.

Selexipag in the management of pulmonary arterial hypertension: an update.

Coghlan JG, Picken C, Clapp LH.

Drug Healthc Patient Saf. 2019 Aug 6;11:55-64. doi: 10.2147/DHPS.S181313. eCollection 2019.

3.

Cardiovascular magnetic resonance-guided right heart catheterization in a conventional CMR environment - predictors of procedure success and duration in pulmonary artery hypertension.

Knight DS, Kotecha T, Martinez-Naharro A, Brown JT, Bertelli M, Fontana M, Muthurangu V, Coghlan JG.

J Cardiovasc Magn Reson. 2019 Sep 9;21(1):57. doi: 10.1186/s12968-019-0569-9.

4.

Pulmonary Hypertension Associated with Connective Tissue Disease.

Fayed H, Coghlan JG.

Semin Respir Crit Care Med. 2019 Apr;40(2):173-183. doi: 10.1055/s-0039-1685214. Epub 2019 May 28.

PMID:
31137058
5.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

6.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
7.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
8.

Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues.

D'Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R.

Heart Fail Clin. 2018 Jul;14(3):467-477. doi: 10.1016/j.hfc.2018.03.011. Review.

PMID:
29966642
9.

Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial.

Vanezis AP, Arnold JR, Rodrigo G, Lai FY, Debiec R, Nazir S, Khan JN, Ng LL, Chitkara K, Coghlan JG, Hetherington SL, McCann GP, Samani NJ.

Heart. 2018 Dec;104(23):1955-1962. doi: 10.1136/heartjnl-2018-313091. Epub 2018 May 10.

10.

Grossly Abnormal Ventilation/Perfusion SPECT Study in Idiopathic Pulmonary Arterial Hypertension Without Thromboembolism.

Chan K, Coghlan JG, Hall M, Haddock J, Bates A, Schreiber BE.

Heart Lung Circ. 2018 Nov;27(11):e101-e104. doi: 10.1016/j.hlc.2018.01.001. Epub 2018 Jan 31.

PMID:
29678310
11.

Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.

Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG.

Eur J Cardiovasc Nurs. 2018 Oct;17(7):612-618. doi: 10.1177/1474515118769534. Epub 2018 Apr 11.

PMID:
29641223
12.

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.

Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E.

Eur Respir J. 2018 Apr 4;51(4). pii: 1701197. doi: 10.1183/13993003.01197-2017. Print 2018 Apr.

13.

Balloon pulmonary angioplasty: does it have a role in CTED?

Coghlan JG.

Pulm Circ. 2018 Jan-Mar;8(1):2045893218754887. doi: 10.1177/2045893218754887. Epub 2018 Jan 8. No abstract available.

14.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

15.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
16.

Pulmonary Arterial Hypertension With Abnormal V/Q Single-Photon Emission Computed Tomography.

Chan K, Ioannidis S, Coghlan JG, Hall M, Schreiber BE.

JACC Cardiovasc Imaging. 2018 Oct;11(10):1487-1493. doi: 10.1016/j.jcmg.2017.07.026. Epub 2017 Oct 18.

17.

Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension.

Connolly MJ, Abdullah S, Ridout DA, Schreiber BE, Haddock JA, Coghlan JG.

Rheumatology (Oxford). 2017 Dec 1;56(12):2197-2203. doi: 10.1093/rheumatology/kex351.

PMID:
29029203
18.

Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension.

Schwaiger JP, Knight DS, Kaier T, Gallimore A, Denton CP, Schreiber BE, Handler C, Coghlan JG.

Echocardiography. 2017 Jun;34(6):817-824. doi: 10.1111/echo.13541. Epub 2017 Jun 13.

PMID:
28612517
19.

Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis.

Schwaiger JP, Loder CD, Dobarro D, Kaier T, Reddecliffe S, Schreiber BE, Handler C, Denton CP, Coghlan JG.

Sci Rep. 2017 Feb 24;7:43304. doi: 10.1038/srep43304.

20.

Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.

Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland.

J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014. Epub 2016 Dec 31.

PMID:
28190786
21.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

22.

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP.

Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25.

23.

Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D'Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S.

J Am Coll Cardiol. 2016 Jul 26;68(4):368-78. doi: 10.1016/j.jacc.2016.05.047.

24.

Exercise pulmonary haemodynamics: a test in search of purpose.

Coghlan JG, Bogaard HJ.

Eur Respir J. 2016 May;47(5):1315-7. doi: 10.1183/13993003.00397-2016. No abstract available. Erratum in: Eur Respir J. 2016 Jul;48(1):285.

25.

Reply.

Sobanski V, Giovannelli J, Denton CP, Coghlan JG.

Arthritis Rheumatol. 2016 Jul;68(7):1789-90. doi: 10.1002/art.39651. No abstract available.

26.

Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature.

Chan E, Sangle SR, Coghlan JG, D'Cruz DD.

Autoimmun Rev. 2016 Apr;15(4):375-8. doi: 10.1016/j.autrev.2016.01.003. Epub 2016 Jan 8. Review.

PMID:
26777307
27.

Left ventricular diastolic dysfunction in pulmonary hypertension predicts functional capacity and clinical worsening: a tissue phase mapping study.

Knight DS, Steeden JA, Moledina S, Jones A, Coghlan JG, Muthurangu V.

J Cardiovasc Magn Reson. 2015 Dec 29;17:116. doi: 10.1186/s12968-015-0220-3.

28.

Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.

Antoniou KM, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, Siafakas NM, Coghlan JG, Denton CP, Hansell DM, Wells AU.

Arthritis Rheumatol. 2016 Apr;68(4):1004-12. doi: 10.1002/art.39528.

29.

Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, Handler CE, Denton CP, Coghlan JG.

Arthritis Rheumatol. 2016 Feb;68(2):484-93. doi: 10.1002/art.39432.

30.

Accuracy and Test-Retest Reproducibility of Two-Dimensional Knowledge-Based Volumetric Reconstruction of the Right Ventricle in Pulmonary Hypertension.

Knight DS, Schwaiger JP, Krupickova S, Davar J, Muthurangu V, Coghlan JG.

J Am Soc Echocardiogr. 2015 Aug;28(8):989-98. doi: 10.1016/j.echo.2015.02.020. Epub 2015 Apr 6.

31.

[Pulmonary hypertension in chronic lung diseases].

Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéy JL.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:142-52. Turkish.

32.

[Pulmonary hypertension due to left heart diseases].

Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:130-41. Turkish.

33.

Accuracy and reproducibility of right ventricular quantification in patients with pressure and volume overload using single-beat three-dimensional echocardiography.

Knight DS, Grasso AE, Quail MA, Muthurangu V, Taylor AM, Toumpanakis C, Caplin ME, Coghlan JG, Davar J.

J Am Soc Echocardiogr. 2015 Mar;28(3):363-74. doi: 10.1016/j.echo.2014.10.012. Epub 2014 Dec 10.

34.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D.

Arthritis Res Ther. 2014 Dec 10;16(6):493. doi: 10.1186/s13075-014-0493-1.

35.

UK resources in the care of adults with Down's syndrome.

Marder L, Coghlan JG.

BMJ. 2014 Oct 21;349:g6295. doi: 10.1136/bmj.g6295. No abstract available.

PMID:
25336293
36.

Scleroderma and breast implants.

Hong C, Sangle SR, Coghlan JG, D'Cruz DP.

QJM. 2015 Jul;108(7):569-70. doi: 10.1093/qjmed/hcu156. Epub 2014 Aug 10. No abstract available.

PMID:
25114282
37.

Prediction of pulmonary complications and long-term survival in systemic sclerosis.

Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP.

Arthritis Rheumatol. 2014 Jun;66(6):1625-35. doi: 10.1002/art.38390.

38.

Pulmonary hypertension in chronic lung diseases.

Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. Review.

39.

Pulmonary hypertension due to left heart diseases.

Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. doi: 10.1016/j.jacc.2013.10.033. Review.

40.

Evidence for the involvement of type I interferon in pulmonary arterial hypertension.

George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, Mohamed NA, Perros F, Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA.

Circ Res. 2014 Feb 14;114(4):677-88. doi: 10.1161/CIRCRESAHA.114.302221. Epub 2013 Dec 13.

41.

Pulmonary hypertension in systemic lupus erythematosus.

Schreiber BE, Connolly MJ, Coghlan JG.

Best Pract Res Clin Rheumatol. 2013 Jun;27(3):425-34. doi: 10.1016/j.berh.2013.07.011. Review.

PMID:
24238697
42.
43.

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR; DETECT study group.

Ann Rheum Dis. 2014 Jul;73(7):1340-9. doi: 10.1136/annrheumdis-2013-203301. Epub 2013 May 18.

44.

Bochdalek hernia causing pulmonary hypertension.

Dobarro D, Schreiber BE, Haddock J, Mandumula S, Coghlan JG.

Circulation. 2013 Apr 30;127(17):1837-9. doi: 10.1161/CIRCULATIONAHA.112.117523. No abstract available.

PMID:
23630087
45.

Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.

Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG.

Am J Cardiol. 2013 Jan 15;111(2):278-85. doi: 10.1016/j.amjcard.2012.09.031. Review.

PMID:
23290599
46.

Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.

Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG.

Arthritis Rheum. 2013 Apr;65(4):1074-84. doi: 10.1002/art.37838.

47.

Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients.

Chighizola C, Meroni PL, Schreiber BE, Coghlan JG, Denton CP, Ong VH.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S81-5. Epub 2012 May 29.

PMID:
22691215
48.

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, Howard LS, Pepke-Zaba J, Sheares KK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA, Peacock AJ.

Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6. doi: 10.1164/rccm.201203-0383OC. Epub 2012 Jul 12.

PMID:
22798320
49.

An update on the evaluation and management of pulmonary hypertension in scleroderma.

Coghlan JG, Schreiber B.

Curr Rheumatol Rep. 2012 Feb;14(1):1-10. doi: 10.1007/s11926-011-0226-2. Review. Erratum in: Curr Rheumatol Rep. 2012 Jun;14(3):294. Schrieber, Benjamin [corrected to Schreiber, Benjamin].

PMID:
22215445
50.

Superior outcome with direct catheter laboratory access vs ED-activated primary percutaneous coronary intervention.

Majumder B, Mavroudis C, Smith C, Coghlan JG, Shiu M, Rakhit RD.

Am J Emerg Med. 2012 Sep;30(7):1118-24. doi: 10.1016/j.ajem.2011.07.016. Epub 2011 Oct 27.

PMID:
22035585

Supplemental Content

Loading ...
Support Center